$SNPS

Glaser Shelagh sold $1.5M of SNPS (indirect holdings)

Glaser Shelagh (CFO) sold 3,394 indirectly-held shares of SYNOPSYS INC (SNPS) at $450.02 ($1.53M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glaser Shelagh
Published Jun 15, 2026, 6:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SNPS
Neutral
high confidence
Mentioned
$SNPS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNPSNeutralLow
01

Why it matters

A senior officer’s open-market sale is disclosed with transaction size, price, and post-transaction holdings; no new operating or market-moving information is provided.

02

Market read

Primarily a sentiment/positioning datapoint; likely limited incremental impact versus broader company fundamentals.

03

What to watch

Traders may over-weight insider sales; without changes in guidance, contracts, or regulatory developments, the signal is usually weak.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15; transaction dated 2026-06-12.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Synopsys.

Company-level read

Ticker impact

$SNPSNeutralHigh confidence
Context

Synopsys CFO Glaser Shelagh filed an SEC Form 4 selling 3,394 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying fundamental catalyst (no guidance, deal, or regulatory action).

Market effects

Minimal; insider selling at a single software name rarely changes sector fundamentals.

Minimal; no cross-asset or macro linkage stated.

Minimal; transaction is company-specific and not tied to global events.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • Synopsys

    Company whose CFO filed the Form 4 insider sale disclosure.

  • Glaser Shelagh

    CFO reporting an open-market sale of SNPS shares under a 10b5-1 plan.

Related articles

$SNPSMedAI 8/10

Agentic AI Is Coming to Chip Design. Here Is Why Synopsys Stock Could Be the Biggest Beneficiary.

Synopsys raised its full-year fiscal 2026 revenue guidance midpoint to $9.665 billion and lifted non-GAAP EPS guidance to $14.76 at the midpoint, driven by strong first-half performance, accelerating Ansys integration synergies, and expanded operating margins. For Q3 fiscal 2026, management guided revenue of $2.41–$2.46 billion and non-GAAP EPS of $3.63–$3.69.

$SNPSMed

Synopsys Just Solved a Bottleneck You Didn’t Even Know Existed

Synopsys' valuation remains difficult to assess on its headline numbers. The forward GAAP price-to-earnings (P/E) makes it look extraordinarily expensive, while the price-to-sales (P/S) ratio does the opposite. The reason is the $35 billion Ansys acquisition. The forward P/E of 138.39x sits 91% above its 5-year average of 72.47x. The Ansys acquisition is holding down the reported earnings, making the stock look inflated.

$SNPSMed

Synopsys Doubles Down on AI Chip Design With Microsoft and AMD. How to Play SNPS Stock Here.

Synopsys (SNPS) shares rose more than 4% after the company unveiled autonomous AI workflows for chip design at the 2026 DAC Chips to Systems Conference. Synopsys said the workflows, built with Microsoft (MSFT) and evaluated by AMD (AMD), can cut debug cycles by 25% to 40%. SNPS reported fiscal Q2 2026 revenue of $2.27B and raised FY2026 outlook to about $9.665B revenue and $14.76 EPS.

$SNPSMed

Synopsys Certifies Its Chip Design Tools on Intel’s 14A Node

Synopsys said it certified its chip design toolchain for Intel’s (INTC) 14A process node, announced July 27, 2026. The certification covers digital and analog implementation, signoff, multiphysics analysis, and node-tuned interface and foundation IP, plus updates to its 3DIC Compiler for Intel packaging. Intel reported 14A foundry revenue not broken out, with $5.8B foundry revenue and a $2.09B operating loss in Q2 2026.

$SNPSMed

Synopsys Should Benefit No Matter Who Wins The AI Race. Here’s What Explains Its Poor Stock Performance.

Synopsys (SNPS) is trading at a forward GAAP P/E of 157.39x, 119% above its 5-year average, which the article attributes to earnings pressure and higher costs tied to its Ansys acquisition. It cites Q2 FY2026 revenue of $2.276B, including $652M from Ansys, and GAAP EPS of $0.09. FY2026 guidance: revenue $9.625B-$9.705B, non-GAAP EPS $14.72-$14.80. Piper Sandler raised its target to $550.